{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:52:14Z","timestamp":1789761134796,"version":"4.0.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sanne H. Tonino has received consultation fees from van Takeda, Incyte Biosciences, Roche Pharma"},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Martine E.D. Chamuleau received financial support for clinical trials from Celgene, Bristol-Myers Squibb, and Gilead."},{"name":"Arjan Diepstra received research funding from Takeda"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Histological transformation of marginal zone lymphoma (tMZL) into diffuse large B-cell lymphoma is associated with poor outcomes. Clinical characteristics associated with transformation risk and outcome after transformation are largely unknown due to scarcity of data. In this population-based study, competing risk analyses were performed to elucidate clinical characteristics associated with developing transformation among 1793 MZL patients using the Netherlands Cancer Registry. Cox regression analyses were performed to elucidate clinical characteristics associated with risk of relapse and mortality after transformation. Transformation occurred in 75 (4%) out of 1793 MZL patients. Elevated LDH and nodal MZL subtype at MZL diagnosis were associated with an increased risk, and radiotherapy with a reduced risk of developing tMZL. Most tMZL patients received R-(mini)CHOP (<jats:italic>n<\/jats:italic>\u2009=\u200953, 71%). Age &gt;60 years and (immuno)chemotherapy before transformation were associated with an increased risk of relapse and mortality after transformation. Two-year progression-free survival (PFS) and overall survival (OS) were 66% (95% CI 52\u201377%) and 75% (95% CI 62\u201385%) for R-(mini)CHOP-treated tMZL patients, as compared to a PFS and OS both of 41% (95% CI 19\u201363%) for patients treated otherwise. Our study offers comprehensive insights into characteristics associated with transformation and survival after transformation, thereby optimizing guidelines and patient counseling.<\/jats:p>","DOI":"10.1038\/s41408-023-00903-w","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T06:01:43Z","timestamp":1693548103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics"],"prefix":"10.1038","volume":"13","author":[{"given":"Johanna A. A.","family":"Bult","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francien","family":"Huisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Veltmaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Kluiver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne H.","family":"Tonino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1628-6256","authenticated-orcid":false,"given":"Joost S. P.","family":"Vermaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0123-9182","authenticated-orcid":false,"given":"Martine E. D.","family":"Chamuleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9239-1050","authenticated-orcid":false,"given":"Arjan","family":"Diepstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-2638","authenticated-orcid":false,"given":"Anke","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter J.","family":"Plattel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6014-4810","authenticated-orcid":false,"given":"Mirian","family":"Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2740-2873","authenticated-orcid":false,"given":"Marcel","family":"Nijland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"903_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720\u201348.","journal-title":"Leukemia."},{"key":"903_CR2","unstructured":"Registry NC Netherlands Comprehensive Cancer Organisation (IKNL). 2022. https:\/\/iknl.nl\/nkr-cijfers."},{"key":"903_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/aol-20-28","volume":"5","author":"JR Cerhan","year":"2021","unstructured":"Cerhan JR, Habermann TM. Epidemiology of marginal zone lymphoma. Ann Lymphoma. 2021;5:1.","journal-title":"Ann Lymphoma"},{"key":"903_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41408-023-00831-9","volume":"13","author":"I Kalashnikov","year":"2023","unstructured":"Kalashnikov I, Tanskanen T, Viisanen L, Malila N, Jyrkki\u00f6 S, Lepp\u00e4 S. Transformation and survival in marginal zone lymphoma: a Finnish nationwide population-based study. Blood Cancer J. 2023;13:62.","journal-title":"Blood Cancer J"},{"key":"903_CR5","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/bjh.14153","volume":"174","author":"AM Maeshima","year":"2016","unstructured":"Maeshima AM, Taniguchi H, Toyoda K, Yamauchi N, Makita S, Fukuhara S, et al. Clinicopathological features of histological transformation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue to diffuse large B-cell lymphoma: an analysis of 467 patients. Br J Haematol. 2016;174:923\u201331.","journal-title":"Br J Haematol"},{"key":"903_CR6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/bjh.17815","volume":"196","author":"G Bastidas-Mora","year":"2022","unstructured":"Bastidas-Mora G, Be\u00e0 S, Navarro A, Gine E, Costa D, Delgado J, et al. Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation. Br J Haematol. 2022;196:146\u201355.","journal-title":"Br J Haematol"},{"key":"903_CR7","doi-asserted-by":"publisher","first-page":"e839","DOI":"10.1016\/j.clml.2021.06.013","volume":"21","author":"CD Rodrigues","year":"2021","unstructured":"Rodrigues CD, Peixeiro RP, Viegas D, Chor\u00e3o P, Couto ME, Gaspar CL, et al. Clinical characteristics, treatment and evolution of splenic and nodal marginal zone lymphomas-retrospective and multicentric analysis of portuguese centers. Clin Lymphoma Myeloma Leuk. 2021;21:e839\u2013e44.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"903_CR8","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1093\/annonc\/mdv368","volume":"26","author":"A Conconi","year":"2015","unstructured":"Conconi A, Franceschetti S, Aprile von Hohenstaufen K, Margiotta-Casaluci G, Stathis A, Moccia AA, et al. Histologic transformation in marginal zone lymphomas\u2020. Ann Oncol. 2015;26:2329\u201335.","journal-title":"Ann Oncol"},{"key":"903_CR9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/annonc\/mdt507","volume":"25","author":"AH Meyer","year":"2014","unstructured":"Meyer AH, Stroux A, Lerch K, Eucker J, Eitle J, Hohloch K, et al. Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma. Ann Oncol. 2014;25:210\u20135.","journal-title":"Ann Oncol"},{"key":"903_CR10","doi-asserted-by":"publisher","first-page":"Jco1800138.","DOI":"10.1200\/JCO.18.00138","volume":"36","author":"JP Alderuccio","year":"2018","unstructured":"Alderuccio JP, Zhao W, Desai A, Gallastegui N, Ramdial J, Kimble E, et al. Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution. J Clin Oncol. 2018;36:Jco1800138.","journal-title":"J Clin Oncol"},{"key":"903_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/ije\/22.3.369","volume":"22","author":"LJ Schouten","year":"1993","unstructured":"Schouten LJ, H\u00f6ppener P, van den Brandt PA, Knottnerus JA, Jager JJ. Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol. 1993;22:369\u201376.","journal-title":"Int J Epidemiol"},{"key":"903_CR12","volume-title":"International classification of diseases for oncology (ICD-O)","author":"World Health O.","year":"2013","unstructured":"World Health O. International classification of diseases for oncology (ICD-O). 1st revision ed. Geneva: World Health Organization; 2013. 3rd2013","edition":"1st revision ed"},{"key":"903_CR13","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project.","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329:987\u201394.","journal-title":"N Engl J Med"},{"key":"903_CR14","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"903_CR15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1365-2141.2012.09054.x","volume":"157","author":"A Conconi","year":"2012","unstructured":"Conconi A, Ponzio C, Lobetti-Bodoni C, Motta M, Rancoita PM, Stathis A, et al. Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol. 2012;157:188\u201396.","journal-title":"Br J Haematol"},{"key":"903_CR16","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/ajh.25446","volume":"94","author":"JP Alderuccio","year":"2019","unstructured":"Alderuccio JP, Zhao W, Desai A, Ramdial J, Gallastegui N, Kimble E, et al. Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation. Am J Hematol. 2019;94:585\u201396.","journal-title":"Am J Hematol"},{"key":"903_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3324\/haematol.2021.278755","volume":"107","author":"CY Cheah","year":"2022","unstructured":"Cheah CY, Zucca E, Rossi D, Habermann TM. Marginal zone lymphoma: present status and future perspectives. Haematologica. 2022;107:35\u201343.","journal-title":"Haematologica."},{"key":"903_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235\u201342.","journal-title":"N Engl J Med"},{"key":"903_CR19","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1182\/bloodadvances.2021004295","volume":"5","author":"M Brink","year":"2021","unstructured":"Brink M, Kahle XU, Vermaat JSP, Zijlstra JM, Chamuleau M, Kersten MJ, et al. Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study. Blood Adv. 2021;5:2958\u201364.","journal-title":"Blood Adv"},{"key":"903_CR20","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s00277-013-1991-y","volume":"93","author":"HR Guirguis","year":"2014","unstructured":"Guirguis HR, Cheung MC, Piliotis E, Spaner D, Berinstein NL, Imrie K, et al. Survival of patients with transformed lymphoma in the rituximab era. Ann Hematol. 2014;93:1007\u201314.","journal-title":"Ann Hematol"},{"key":"903_CR21","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1097\/01.HS9.0000847544.35248.88","volume":"6","author":"F Huisman","year":"2022","unstructured":"Huisman F, Al-sarayfi D, Bellido M, Mous R, Vermaat JS, Kater AP, et al. P1170: incidence, treatment and outcome of patients with Richter\u2019s syndrome: a population-based cohort study in the Netherlands. Hemasphere. 2022;6:1056\u20137.","journal-title":"Hemasphere"},{"key":"903_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s11864-019-0687-5","volume":"20","author":"A Sindel","year":"2019","unstructured":"Sindel A, Al-Juhaishi T, Yazbeck V. Marginal zone lymphoma: state-of-the-art treatment. Curr Treat Options Oncol. 2019;20:90.","journal-title":"Curr Treat Options Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00903-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00903-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00903-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T09:03:59Z","timestamp":1700298239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00903-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["903"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00903-w","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]},"assertion":[{"value":"2 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ST received consultation fees from van Takeda, Incyte Biosciences, and Roche Pharma. MC received financial support for clinical trials from Celgene, Bristol-Myers Squibb, and Gilead. AD received research funding from Takeda. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}